D. D. Depestel and D. M. , Aronoff, «Epidemiology of Clostridium difficile infection, J Pharm Pract, vol.26, pp.464-475, 2013.

F. Barbut, J. Meynard, and C. Eckert, «Traitement des infections digestives à Clostridium difficile : anciennes et nouvelles approches, 2011.
DOI : 10.1016/j.antinf.2011.03.002

F. Barbut, B. Guery, and C. Eckert, «Comment traiter une infection digestive à Clostridium difficile en 2014 ?,» Réanimation, n° %123, pp.284-297, 2014.
DOI : 10.1007/s13546-014-0867-z

S. Buyse, E. Azoulay, F. Barbut, and B. Schlemmer, «Infection à Clostridium difficile : physiopathologie, diagnostic et traitement,» Réanimation, pp.1255-263, 2005.

E. Kipnis, K. Faure, B. Guery, ». «clostridium-difficile, and . Mapar, , 2008.

F. Barbut, «Actualités sur l'épidémiologie et le diagnostic des infections à Clostridium difficile (ICD),» chez Journée annuelle d'échange, 2017.

J. Freeman, M. Bauer, S. Baines, J. Corver, W. Fawley et al.,

. Wilcox, «The changing epidemiology of Clostridium difficile infections, Clinical Microbiology Reviews, vol.23, pp.529-549, 2010.

E. J. Kuijper, F. Barbut, J. S. Brazier, N. Kleinkauf, T. Eckmanns et al.,

B. Delmée, M. Coignard, B. Wilcox, R. Patel, E. Frei et al.,

A. Âkerlund, O. Virolainen-julkunen, S. Lyytikäinen, A. Kotila, and B. Ingebretsen,

P. Smyth, I. R. Rooney, D. L. Poxton, and . ;-»-eurosurveillance, Monnet, «Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, vol.13, p.18492, 2008.

J. Nau, «Clostridium difficile : une épidémie au service de la santé publique, Revue Médicale Suisse, vol.2, p.2274, 2006.

, European Centre for DiseasePrevention and Control, «Healthcare-associated infections: Clostridium difficile infections,» ECDC. Annual Epidemiological Report for, 2016.

C. Eckert, B. Coignard, M. Hebert, C. Tarnaud, C. Tessier et al., Barbut et ICD-Raisin Working Group, «Clinical and microbiological features of Clostridium difficile infections in France: The ICD-RAISIN 2009 national survey, Médecine et maladies infectieuses, vol.43, pp.67-74, 2013.

F. Barbut, L. Ramé, A. Petit, L. Suzon, A. De-chevigny et al., «Prévalence des infections à Clostridium difficile chez les patients hositalisés avec une diarrhée : résultats d'une étude français prospecive multicentrique,» La Presse Médicale, vol.44, pp.75-83, 2014.
DOI : 10.1016/j.lpm.2014.09.021

A. Gupta and S. Khanna, «Community-acquired Clostridium difficile infection: an increasing public health threat,» Infection and Drug Resistance, vol.7, pp.63-72, 2014.

A. S. Chitnis, S. M. Holzbauer, R. M. Belflower, L. G. Winston, W. M. Bamberg et al.,

M. M. Lyons, G. K. Farley, L. E. Dumiyati, Z. G. Wilson, J. R. Beldavs et al., «Epidemiology of community-associated Clostridium difficile infection, vol.173, pp.1359-1367, 2009.

S. Khanna, D. S. Pardi, S. L. Aronson, P. P. Kammer, R. Orenstein et al., «The epidemiology of community-acquired Clostridium difficile infection: a population-based study, » American Journal of Gastroenterology, vol.107, issue.%11, pp.89-95, 2012.

G. Kim and N. A. Zhu, Canadian Family Physician, vol.63, pp.97-99, 2017.

E. O'toole and I. C. Hall, «Intestinal Flora in New-Born Infants with a Description of a New Pathogenic Anaerobe, Bacillus Difficile, vol.49, pp.1390-402, 1935.

J. G. Barlett, N. S. Taylor, T. Chang, and J. Dzink, «Clinical and laboratory observations in Clostridium difficile colitis, Am J Clin Nutr, vol.33, pp.12521-2526, 1980.

H. Kato, N. Kato, K. Watanabe, N. Iwai, and H. Nakamura, «Identification of Toxin Anegative, Toxin B-positive Clostridium difficile by PCR, vol.36, pp.2178-2182, 1998.

F. Barbut, V. Lalande, B. Burghoffer, H. Vu-thien, E. Grimpel et al., «Prevalence and genetic characterization of Toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France, J Clin Microbiol, pp.2079-2083, 2002.

D. Lyerly, L. Barroso, T. Wilkins, C. Depitre, and G. Corthier, «Characterization of a Toxin A-negative, Toxin B-positive strain of Clostridium Difficile, vol.60, pp.4633-4639, 1992.

F. C. Lessa, C. V. Gould, and L. C. Mcdonald, «Current status of Clostridium difficile infection epidemiology, vol.55, 2012.

F. Barbut and J. Petit, «Epidemiology of Clostridium difficile associated infections, vol.17, pp.405-410, 2001.

L. Mcfarland, M. Mulligan, and R. Kwork, «Nosocomial acquisition of Clostridium difficile infection, N ENgl J Med, vol.320, pp.204-214, 1989.

M. M. Neranzic, M. J. Pultz, and C. J. Donskey, «Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection, Antimicrobial Agents and Chemotherapy, vol.53, pp.4133-4137, 2009.

E. Sager and V. Ngoya, Camus-Bouedjoro, «Les infections à Clostridium difficile en EHPAD»

M. B. Debast, M. P. Bauer, and E. J. Kuijper, «European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection, Clinical Microbiology and Infection, vol.20, pp.1-26, 2014.

S. Aslam, R. J. Hamill, and D. M. Musher, «Treatment of Clostridium difficile associated disease: old therapies and new strategies,» Lancet Infect Dis, n° %15, pp.549-57

I. Ramsay, N. M. Brown, and D. A. Enoch, «Recent Progress for the Effective Prevention,» Infectious Diseases: Research and Treatment, vol.11, pp.1-4, 2018.

L. M. Napolitano and C. E. Edmiston, , 2017.

A. Shen, «Clostridium difficile toxins: Mediators of inflammation, J Innate Immun, vol.4, pp.149-158, 2012.

, «Conduite à tenir : diagnostic, investigation, surveillance, et principes de prévention et de maitrise des infections à Clostridium difficile, vol.26, p.5, 2006.

A. L. Monnier, E. Bille, V. Bourgeois-nicolaos, V. Cattoir, E. Farfour et al., «Asymptomatic carriage of Clostridium difficile in French hospitals: preliminary results of the PORTADIFF study, 2017.

K. Heaton, J. Radvan, H. Cripps, R. Mountford, F. Braddon et al., «Defecation frequency and timing, and stool form in the general population: a prospective study, » Gut, vol.33, pp.818-824, 1992.

C. Eckert, V. Lalande, and F. Barbut, «Diagnostic des infections à Clostridium difficile, pp.67-73, 2011.

M. Crobach, T. Planche, C. Eckert, F. Barbut, E. Terveer et al.,

«. Kuijper, Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection,» Clinical Microbiology and Infection, n° %122, pp.63-81, 2016.

M. H. Wilcox, H. Ahir, J. E. Coia, A. Dodgson, S. Hopkins et al., «Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life, J Antimicrob Chemother, vol.72, pp.2647-2656, 2017.

F. Barbut, T. Galperine, P. Vanhems, A. L. Monnier, V. Jeanbat et al.,

C. Alami, F. Bensoussan, and . Fagnani, «Impact of Clostridium difficile infection on patients' quality of life, a French hospital prospective study, » OFID, vol.4, issue.1, p.393, 2017.

A. L. Monnier, A. Duburcq, J. R. Zahar, S. Corvec, T. Guillard et al.,

V. Woerther, V. Fihman, H. Lalande, A. Jacquier, E. Mizrahi et al., «Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals, Journal of Hospital Infection, vol.91, pp.117-122, 2015.

E. Ramirez and E. S. Bouza, «Updates on Clostridium difficile in Europe,» Advances in Experimental Medicine and Biology 1050, vol.8, pp.1-12, 2018.

M. M. Soriano and S. Johnson, «Treatment of Clostridium difficile Infections,» Infect Dis Clin N Am, 2015.

C. L. Mcdonald, D. N. Gerding, S. Johnson, J. S. Bakken, K. C. Carroll et al.,

J. Sandora and M. H. Wilcox, «Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA, Clinical Infectious Diseases, vol.66, pp.1-48, 2018.

«. Astellas, D. Légales, and ». ,

T. J. Louie, M. A. Miller, K. M. Mullane, K. Weiss, A. Lentnek et al., «Fidaxomicin versus Vancomycin for Clostridium difficile infection, vol.364, pp.422-453, 2011.

V. Andre and «. , , 2015.

J. Walton, D. Burns, and K. E. Gaehle, «Process and outcome of fecal microbiota transplants in patients with recurrent Clostridium difficile infection, » Society of Gastroenterology Nurses and Associates, vol.40, pp.411-419, 2017.

T. Galpérine, B. Guéry, and F. G. , Transplantation, «Exploring ways to improve CDI outcomes,» Médecine et maladies infectieuses, 2017.

J. G. Barlett, «Clostridium difficile infection,» Infect Dis Clin N Am, n° %131, pp.489-495, 2017.

F. Tissot and M. Maillard, «Colite à Clostridium difficile : nouvelles recommandations de prise en charge,» n° %110, pp.913-922, 2014.

E. Van-nood, A. Vrieze, and M. Nieuwdorp, «Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med, pp.407-415, 1368.

C. F. Manthey and L. , Eckmann et V. Fuhrmann, «Therapy for Clostridium difficile infection -any news beyond Metronidazole and Vancomycin ?, » Expert Review of Clinical Pharmacology, vol.110, issue.11, pp.1239-1250, 2017.

, Direction Générale de la Santé, «Avis du Comité technique des infections nosocomiales et des infections liées aux soins relatif à la maîtrise de la diffusion des infections à Clostridium difficile dans les établissements de santé français, 2006.

S. Tschudin-sutter, E. J. Kuijper, A. Durovic, M. G. Vehreschild, F. Barbut et al., Widmer, «Guidance document for prevention of Clostridium difficile infection in acute healthcare settings, Clinical Microbiology and Infection, vol.24, pp.1051-1054, 2018.

J. Joseph, S. Singhal, G. M. Patel, and S. Anand, «Clostridium difficile Colitis : Review of the Therapeutic Approach, vol.121, pp.385-394, 2014.

N. Popovic, M. Korac, Z. Nesic, B. Milosevic, A. Urosevic et al., Barac et I. Milosevic, «Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study, European Journal of Clinical Microbiology & Infectious Diseases, 2018.

T. E. Asempa and D. P. Nicolau, «Clostridium difficile infection in the elderly : an update on management, Clinical Interventions in Aging, vol.112, pp.1799-1809, 2017.

F. Rafiullah, S. Kanwal, U. M. Majeed, M. A. Korsten, F. H. Cheema et al., Rizwan Sohail, «Successful use of nitazoxanide in the treatment of reccurent Clostridium difficile infection, BMJ Case Reports, 2011.

I. A. Critchley, L. S. Green, C. L. Young, J. M. Bullard, R. J. Evans et al.,

J. W. Jarvis, N. Guiles, and U. A. Janjic, Ochsner, «Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile, Journal of Antimicrobial Chemotherapy, vol.163, pp.954-963, 2009.

U. A. Ochsner, S. J. Bell, A. L. O'leary, T. Hoang, K. Stone et al., Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model, Journal of Antimicrobial Chemotherapy, issue.63, pp.964-971, 2009.

D. M. Citron, Y. A. Warren, K. L. Tyrrell, V. Merriam, and E. J. Goldstein, «Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria, Journal of Antimicrobial Chemotherapy, vol.169, pp.972-976, 2009.

S. U. Nayak, J. Mcleod-griffiss, J. Blumer, M. A. O'riordan, W. Gray et al.,

. Zenilman, and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile, in a Phase I study, Antimicrobial Agents and Chemotherapy, vol.61, p.18, 2017.

D. N. Gerding, O. A. Cornely, S. Grill, H. Kracker, A. C. Marrast et al.,

M. Talbot, I. G. Buitrago, C. M. Diaconescu, L. De-oliveira, J. Preotescu et al.,

J. Louie and M. H. Wilcox, «Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase III trials, Lancet Infectious Diseases, 2019.

P. Daley, T. Louie, J. Lutz, S. Khanna, U. Stoutenburgh et al., «Surotomycin versus vancomycin in adults with Clostridium difficile infection : primary clinical outcomes from the second pivotal, randomised, double-blind, phase III trial, The journal of antimicrobial chemotherapies, vol.72, pp.3462-3470, 0112.

K. Mullane, C. Lee, A. Bressler, M. Buitrago, K. Weiss et al., Blais et P. Pertel, «Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections, Antimicrobial Agents and Chemotherapy, vol.59, p.13, 2015.

H. Maxwell-scott and S. Goldenberg, «Existing and investigational therapies for the treatment of Clostridium difficile infection : a focus on narrow spectrum, microbiotasparing agents,» Médecine et maladies infectieuses, n° %148, pp.1-9, 2018.

E. Van-nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E. G. Zoetendal et al., «Duodenal infusion of donor feces for recurrent Clostridium difficile, N Engl J Med, vol.368, pp.407-422, 2013.

H. Sokol, T. Galperine, N. Kapel, P. Bourlioux, P. Seksik et al., «Transplantation de microbiote fécal dans le cadre des infections à Clostridium difficile récidivantes : recommandations pour la pratique courante,» Hepato-gastro et oncologie digestive, vol.22, p.14, 2015.

G. Cammarota, G. Ianiro, H. Tilg, M. Rajilic-stojanovic, P. Kump et al.,

G. Scaldaferri, A. Gasbarrini, A. Lopez-sanroman, P. Link, W. De-groot et al.,

M. Sanguinetti, A. Simren, and . Gasbarrini, «European consensus conference on faecal microbiota transplantation in clinical practice,» Gut, n° %10, pp.1-12, 2017.

K. Rao, V. B. Young, and P. N. Malani, «Capsules for fecal microbiota transplantation in recurrent Clostridium difficile infection, JAMA, vol.318, 1979.

T. Galpérine, «Quel avenir pour la Transplantation de Microbiote Fécal en thérapeutique ?,» chez 8ème journée de l'intergroupe SPILF/SFGG

, American Gastroenterological Association

P. Panchal, S. Budree, A. Scheeler, G. Medina, M. Seng et al.,

Z. Mitchell, J. R. Kassam, M. Allegretti, and . Osman, «Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future, vol.20, p.114, 2018.

J. Martin and M. Wilcox, «New and emerging therapies for Clostridium difficile infection,» Current Opinion Infectious Disease, vol.29, pp.546-554, 2016.

E. R. Dubberke, C. H. Lee, R. Orenstein, S. Khanna, G. Hecht et al., «Results from a randomized placebo-controlled clinical trial of a RBX2660 -a microbiota-based drug for the prevention of reccurent Clostridium difficile infection, Clinical Infectious Disease, vol.29, p.3, 2018.

S. Pasteur,

. Valneva,

. Pfizer, Pfizer announces positive top-line results from phase 2 study of investigational Clostridium difficile vaccine for the prevention of C. Difficile infection

L. «dictionnaire and ». Ligne,

A. J. Biller, A. J. Katz, A. F. Flores, T. M. Buie, and S. L. Gorbach, «Case report: Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG, vol.21, pp.224-226, 1995.

M. Segarra-newnham, «Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii, vol.41, pp.1212-1221, 2007.

B. Biocodex and S. Boulardii, , 2017.

L. V. Mcfarland, C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer et al.,

S. A. Moyer, K. E. Melcher, J. L. Bowen, Z. Cox, G. Noorani et al., «A randomized placebo-controlled trial of S. boulardii in combination with standard antibiotics for Clostridium difficile disease, The Journal of the American Medical Association, vol.271, pp.1913-1918, 1994.

C. M. Surawicz, L. V. Mcfarland, R. N. Greenberg, M. Rubin, R. Fekety et al.,

R. J. Mulligan, S. Garcia, K. Brandmarker, D. Bowen, G. W. Borjal et al., «The search for a better treatment for recurrent Clostridium difficile disease: use of highdose vancomycin combined with S. boulardii, Clinical Infectious Disease, vol.31, pp.1012-1017, 2000.

H. Duboc, C. C. Nguyen, D. Rainteau, B. Coffin, L. Humbert et al.,

. Ciaran, «Saccharomyces boulardii freine l'augmentation de l'acide cholique durant une antibiothérapue chez le volontaire sain : un nouveau mécanisme potentiel dans la protection des diarrhées à Clostridium difficile,» chez JFHOD, 2017.

L. V. Mcfarland, «Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease, » American Journal of Gastroenterology, vol.101, pp.812-822, 2006.

J. M. Tung, L. R. Dolovich, and C. H. Lee, «Prevention of Clostridium difficile infection with S. boulardii: a systematic review, Can J Gastroenterol, vol.23, pp.817-821, 2009.

E. J. Goldstein, S. J. Johnson, P. Maziade, C. T. Evans, J. C. Sniffen et al., «Probiotics and prevention of Clostridium difficile infection, vol.45, pp.114-119, 2017.

N. T. Shen, A. Maw, L. L. Tmanova, A. Pino, K. Ancy et al., Evans, «Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis, » Gastroenterology, vol.152, pp.1889-1900

T. Beinortas, N. E. Burr, M. H. Wilcox, and V. Subramanian, «Comparative efficacy of treatments for Clostridium difficile infection : a systematic review and network metaanalysis,» The Lancet, vol.16, p.7, 2018.

A. L. Shane, R. K. Mody, J. A. Crump, P. I. Tarr, T. S. Steiner et al.,

C. Langley, C. A. Wanke, A. C. Warren, J. Cheng, L. K. Cantey et al., , p.2017

, Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea,» Clinical Infectious Diseases, pp.1-36, 2017.